[{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Raises \u20ac5.0m Following Its Successful Initial Public Offering on Euronext Growth Paris\u00ae","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL BIOSCIENCES: Phase II\/III clinical trial for NFL-101 For Smoking Cessation Approved in France","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL BIOSCIENCES: Approval for Its Patent to Be Granted in The United States","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Diverchim S.A.","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences: Agreement Signed with Diverchim to Manufacture Its Active Ingredients","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Phase II\/III Clinical Trial Launched for Smoking Cessation","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL BIOSCIENCES: Notice of Allowance of Its Patent In China","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences to Present at the H.C.wainwright 1st Annual Mental Health Conference","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Artemis Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: New Patent Application Associating NFL-101 With Other Smoking Cessation Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"French Government","pharmaFlowCategory":"D","amount":"$0.2 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Receives a Joint Grant from The French Government and The Occitanie Region for its PRECESTO Clinical Trial","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: CESTO II Trial Progressing On Schedule","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Launches a Round of Fundraising for Approximately 2.5 Million Euros","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"CEA","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tobacco Addiction: NFL Biosciences Collaborates with The CEA To Study the Mechanism of Action of Its Drug Candidate NFL-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Athena Pharmaceutiques","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NFL BIOSCIENCES: Co-development Agreement For A Drug Candidate to Reduce Alcohol Consumption","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2022","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Bpifrance","pharmaFlowCategory":"D","amount":"$1.8 million","upfrontCash":"Undisclosed","newsHeadline":"NFL Biosciences Receives \u20ac 1.7 Million In \u00ab Avance Innovation \u00bb Funding From Bpifrance","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Inclusion Of the First Volunteer in The PRECESTO Study, Which Aims to Demonstrate the Complementarity Of NFL-101 With Other Smoking Cessation Treatments","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"NFL Biosciences: Recruitment Completed for The PRECESTO Study","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by NFL Biosciences
NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is being evaluated for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is under phase I trials, for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
The funding will be used to complete the CESTO II clinical study designed to evaluate the efficacy and safety of its NFL-101 (tobacco leaf protein) treatment as a smoking cessation therapy.
Under the terms of the collaboration, NFL-Biosciences will use the CEA's molecular imaging resources to better understand the mechanism of action of NFL 101. NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families.
The funding will be used for the CESTO II phase II/III trial, aiming to demonstrate the efficacy of its botanical drug candidate NFL-101 for smoking cessation and and the PRECESTO trial, assessing the potential of NFL-101 for nicotine replacement therapies.
NFL-101 (tobacco leaf protein) is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is under phase I trials, for reduction in the desire to smoke, without any toxicity which also reduces tobacco allergies.
NFL-101 is a standardized, nicotine-free tobacco leaf extract protected by two patent families. NFL Biosciences intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative.
NFL-101, is a standardized, nicotine-free tobacco leaf extract protected by two patent families, intends to offer smokers who want to quit a natural, safe, easy-to-administer and personalized alternative.
Under the partnership to develop NFL-101, the company’s drug candidate Tobacco leaf protein for smoking cessation, for the Indian market with Themis Medicare Ltd., will purchase Active Pharmaceutical Ingredient (API) from NFL Biosciences.
NFL-101 (tobacco leaf protein), is a natural product based on a standardized extract of tobacco leaf patented, botanical drug candidate that aims at increasing the odds of quitting for smokers willing to quit.